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BACKGROUND
Asthma and allergy are leading causes of morbidity in childhood,
and in some cases may lead to mortality.1 Although the
prevalence of asthma may have reached a plateau in some
developed country settings, data suggest that the prevalence of
other allergic disorders, such as food allergy, may be rising.2 The
overall burden of asthma and allergy transcends individual,
familial and societal contexts, and it presents a challenge
to public healthcare systems in terms of prevention and
management of symptoms.3–8 The propensity to develop
asthma or allergy is at least partially established before birth,
resulting from the interplay between genetic predisposition and
environmental exposures.9,10
It is now increasingly understood that known and unknown
prenatal environmental exposures play their part, importantly
during fetal development.11 A number of studies have investi-
gated the role of several fetal environmental exposures, including
maternal obesity, inhaled pollutants (such as tobacco smoke and
diesel exhaust fumes) and ingestion of paracetamol during
pregnancy.12–16 In addition to these prenatal exposures, recent
emerging evidence indicates that the use of acid-suppressive
medications by mothers during pregnancy may increase the risk
of development of asthma and allergy in the offspring.17–20
Reported increased risk of asthma when the expectant mother is
exposed to acid-suppressive drugs ranges from 32%19 to 57%,21
although for other allergic diseases reported data are inconsistent.
The precise underlying pathophysiological mechanism for the
role of acid-suppressive medications in the development of
asthma is not clearly understood. Dehlink et al.17 suggested three
mechanisms by which maternal acid-suppressive therapy may
promote allergy in the progeny: (i) gastric acid suppression could
interfere with digestion of labile antigens in the maternal stomach
and increase the amount of allergen the foetus is exposed to and
results in sensitisation; (ii) acid-suppressive medications may
induce a Th2 cytokine pattern in mothers, promoting an allergy-
prone state in the fetus; or (iii) maternal allergen-speciﬁc
immunoglobulin E could cross fetal membranes and induce
sensitisation of fetal immune cells to food and airborne allergens
before birth. In a study conducted in adults, immunoglobulin E
sensitisation was detected ﬁve months after discontinuation of
treatment with acid-suppressive medication.22
Acid-suppressive medications are commonly used in the
management of gastro-oesophageal reﬂux and heartburn symp-
toms, which are frequently reported by expectant mothers.23,24
Although the prescription of any drug should be carefully re-
evaluated during pregnancy, some substances have become over-
the-counter drugs for pregnant women even if their precise
impact on the fetus has not been deﬁnitively evaluated.25 Given
the widespread use of gastric-acid-suppressing medications
during pregnancy, their role in the development of asthma and
allergic disorders in the offspring raises potential public health
concern. To appreciate the emerging evidence base, there is now
a need to comprehensively synthesise the available primary
studies. By bringing together all relevant data, the underlying role
of acid-suppressive medications in the development of asthma
and allergy could be clariﬁed, which would eventually provide the
opportunity for initiating primary prevention interventions.
AIMS AND OBJECTIVES
We aim to identify, critically appraise and undertake meta-analysis
of studies on the association between the use of acid-suppressive
medications during pregnancy and the development of asthma
and allergic disorders in the offspring.
Speciﬁc objectives are as follows:
1. To study the associations between maternal use of H2 receptor
antagonists, proton pump inhibitors and antacids during
pregnancy and the risk of asthma and allergy in the offspring.
2. To identify whether the association between acid-suppressive
medications (H2 receptor antagonists, proton pump inhibitors
and antacids) and asthma and allergy varies according to the (i)
timing; (ii) frequency; or (iii) dose of intake.
METHODS
Study eligibility criteria
Types of studies. We will include all cohort studies, case–control
studies and cross-sectional studies investigating the association
between acid-suppressive medications in pregnant mothers and
allergy/asthma outcomes in their offspring. We will exclude
reviews, case studies and case series, and animal studies. We will
include conference abstracts in a table of unpublished studies.
There will be no minimum number of participants or minimum
length of follow-up required in the studies to be considered for
inclusion.
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Types of participants. We will include studies involving women
of any age during preconception and pregnancy and their
offspring who are o17 years old.
Types of exposure. We will include all studies that have
investigated the associations between maternal use of acid-
suppressive medications (H2 receptor antagonists, proton pump
inhibitors and antacids) during pregnancy and the risk of asthma
and allergy in the offspring.
Types of outcome measures. Primary outcomes will include self-
reported or objectively deﬁned asthma, atopic dermatitis/eczema,
allergic rhinitis or hayfever; anaphylaxis and urticaria and food
allergy reported by physician or hospital record; and atopic
sensitisation as deﬁned either by skin-prick test or raised antigen-
speciﬁc immunoglobulin E.
Secondary outcomes will include objective and subjective
measures of disease severity and impact on quality of life,
including asthma exacerbations, the use of asthma medications,
hospitalisation for asthma, wheeze as deﬁned by self-report or
objective diagnosis, indicators of airway function (peak expiratory
ﬂow, forced expiratory volume in 1 s, forced vital capacity, forced
expiratory ﬂow rate or alternative age appropriate pulmonary
function tests (oscillometry or exhaled nitric oxide analysis)) and
measures of health-related quality of life.
Search strategy
To identify studies for the review, we will search the following
international electronic databases: MEDLINE (Ovid), EMBASE
(Ovid), Web of Science CORE (Thomson Reuters), BIOSIS (Thomson
Reuters), CINAHL (Cumulative Index to Nursing and Allied Health
Literature; EBSCO), Cochrane Library (CDSR; Wiley), Global Health
CABI (Ovid), Global Health Library (Global Index Medicus), Scopus,
Popline and Google Scholar. Additional studies will be retrieved by
searching the references of identiﬁed eligible papers and by
contacting a panel of international experts on the topic.
Conference abstracts will be retrieved through search of ISI
Conference Proceedings Citation Index via Web of Knowledge and
ZETOC (British Library). Unpublished and in-progress studies will
be identiﬁed by searching online trial registries such as Current
Controlled Trials, ClinicalTrials.gov, Australian and New Zealand
Clinical Trials Registry. All databases will be searched from
inception to 2015. No language restrictions will be imposed; for
foreign language publications, translations will be sought where
possible. All eligible studies identiﬁed will be manually checked to
trace any original studies not identiﬁed via this search.
Supplementary Appendix 1 presents details of our search strategy,
which was developed in MEDLINE and will be adapted in
searching other databases.
Screening of retrieved literature. The titles and abstracts of all
papers retrieved from the databases will be checked
independently by two reviewers against the criteria of the study.
The full texts of papers that are potentially eligible will be
retrieved and further assessed for inclusion independently by
two reviewers. Any discrepancies in the screening processes
between the two reviewers will be resolved by consensus, and
disagreements will be arbitrated by a third reviewer.
Data extraction
A customised data collection form will be used by two reviewers,
independently, to extract relevant study data from full-text papers
selected for inclusion. The form will be piloted and reﬁned before
being applied to all full-text reports. Where necessary, clariﬁcation
and additional data will be sought from study authors. Key
ﬁndings from each included study will be summarised and
tabulated. Any discrepancies in data extraction between the two
reviewers will be resolved by consensus, and disagreements will
be arbitrated by a third reviewer.
Quality assessment
Quality assessment and risk of bias assessment of studies will be
undertaken using the Effective Public Health Practice Project tool
(http://www.ephpp.ca/).
Data synthesis
Data will be presented in a narrative and tabular form. Where
possible, meta-analysis will be performed on clinically,
methodologically and statistically comparable studies
(comparable particularly with respect to study design, exposure
measures and assessment, and outcomes and assessment) using
random-effects models. Heterogeneity will be assessed using the
I-squared statistic. Where possible, depending on reporting in
original studies, sensitivity and subgroup analyses will be
performed. Subgroup analysis will be performed based on
participants’ characteristics, including the trimester at the time
of intake of acid-suppressive medications, dosage and duration of
intake. Sensitivity analysis will be performed to explore the source
of heterogeneity, e.g., based on study quality or risk of bias.
Publication bias will be explored using funnel plots and will
be estimated using Begg and Egger tests.26,27 Comprehensive
Meta-Anaysis software will be used for the meta-analysis.
Registration and reporting
This study will be registered on the University of York Centre for
Reviews and Dissemination International prospective register
of systematic reviews (PROSPERO). We will report according to
the PRISMA guidelines for reporting of systematic reviews and
MOOSE guidelines for observational epidemiological systematic
reviews.28,29
DISCUSSION AND CONCLUSION
Current understanding indicates that the fetal period is critical for
the onset of common chronic disorders later in childhood,
including asthma and allergy, whose susceptibility is now believed
to be already established in utero as a result of the interplay of
both genetic and environmental factors on the developing
immune system.11,30 The identiﬁcation of speciﬁc modiﬁable
environmental factors offers a real possibility of enhancing our
understanding of the underlying disease mechanisms and
development of early potential preventive strategies.
The emerging evidence indicating that prenatal use of
acid-suppressive medications may increase the risk of asthma
and allergy in the offspring may constitute a public health concern
given that these medications are commonly used for the
treatment of gastro-oesophageal reﬂux and heartburn symptoms
during pregnancy. However, given mixed evidence now reported
by studies on this topic, a comprehensive synthesis of the
evidence is essential in the following: (i) clarifying the putative role
of acid-suppressive medications in the development of asthma
and allergy in children; (ii) clarifying whether the different
commonly used acid-suppressive medications (H2 receptor
antagonists, proton pump inhibitors and antacids) and their doses
are differentially associated with the risk of asthma and allergy in
children; (iii) clarifying whether there is a critical time window of
exposure to acid-suppressive medications during pregnancy that
maximises the risk of asthma and allergy in the offspring; (iv)
identifying subgroups of mothers and their offspring that
may beneﬁt or are at high risk of exposure to prenatal exposure
to acid-suppressive medications; and (v) identifying potential
research gaps in this evidence base that will need to be taken into
account going forward.
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We anticipate that there may be clinical, methodological and
statistical heterogeneity in the studies we identify for inclusion.
These factors will be taken into consideration in the decision
on whether to pool data and also to ensure appropriate
interpretation of ﬁndings.
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